​

Acelyrin (SLRN) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

SLRN Stock Forecast

Acelyrin (SLRN) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $10.50, with a high of $15.00 and a low of $6.00. This represents a 362.56% increase from the last price of $2.27.

- $3 $6 $9 $12 $15 High: $15 Avg: $10.5 Low: $6 Last Closed Price: $2.27

SLRN Stock Rating

Acelyrin stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (50.00%), 3 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 3 3 Strong Sell Sell Hold Buy Strong Buy

SLRN Price Target Upside V Benchmarks

TypeNameUpside
StockAcelyrin362.56%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.27$2.27$2.27
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25-2---2
May, 25-2---2
Apr, 25-2---2
Mar, 2512---3
Feb, 25133--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 16, 2024Derek ArchilaWells Fargo$15.00$5.72162.24%560.79%
Aug 14, 2024Samantha SemenkowCitigroup$6.00$4.0647.78%164.32%
Mar 20, 2024Derek ArchilaWells Fargo$13.00$8.3256.25%472.69%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 14, 2024Cowen & Co.BuyBuyhold
Oct 16, 2024Wells FargoOverweightOverweighthold
Sep 25, 2024Piper SandlerOverweightOverweighthold
Aug 14, 2024Cowen & Co.BuyBuyhold
Aug 14, 2024CitigroupNeutralNeutralhold
Aug 14, 2024Piper SandlerOverweightOverweighthold
Aug 14, 2024H.C. WainwrightBuyNeutraldowngrade
Jul 08, 2024Wells FargoOverweightupgrade
May 24, 2024Piper SandlerOverweightOverweighthold
May 10, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-11 $-9 $-7 $-5 $-3 $-1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.43$-2.50----
Avg Forecast$-7.14$-2.50$-2.13$-2.06$-2.04$-1.33
High Forecast$-4.09$-2.37$-1.53$-1.31$-1.35$-1.33
Low Forecast$-10.71$-2.63$-2.66$-3.12$-2.44$-1.33
Surprise %-23.95%-----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$9.88M$160.19M$86.39M
High Forecast---$9.88M$160.19M$86.39M
Low Forecast---$9.88M$160.19M$86.39M
Surprise %------

Net Income Forecast

$-800M $-650M $-500M $-350M $-200M $-50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-381.64M$-248.23M----
Avg Forecast$-381.64M$-175.65M$-147.06M$-155.71M$-133.24M$-93.43M
High Forecast$-287.28M$-166.55M$-107.39M$-92.04M$-95.17M$-93.43M
Low Forecast$-752.08M$-184.75M$-186.73M$-219.38M$-171.30M$-93.43M
Surprise %-41.32%----

SLRN Forecast FAQ

Is Acelyrin stock a buy?

Acelyrin stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Acelyrin is a favorable investment for most analysts.

What is Acelyrin's price target?

Acelyrin's price target, set by 6 Wall Street analysts, averages $10.5 over the next 12 months. The price target range spans from $6 at the low end to $15 at the high end, suggesting a potential 362.56% change from the previous closing price of $2.27.

How does Acelyrin stock forecast compare to its benchmarks?

Acelyrin's stock forecast shows a 362.56% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Acelyrin over the past three months?

  • June 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Acelyrin’s EPS forecast?

Acelyrin's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.13, marking a -14.80% decrease from the reported $-2.5 in 2024. Estimates for the following years are $-2.06 in 2026, $-2.04 in 2027, and $-1.33 in 2028.

What is Acelyrin’s revenue forecast?

Acelyrin's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $9.88M, followed by $160.19M for 2027, and $86.39M for 2028.

What is Acelyrin’s net income forecast?

Acelyrin's net income forecast for the fiscal year ending in December 2025 stands at $-147M, representing a -40.76% decrease from the reported $-248M in 2024. Projections indicate $-156M in 2026, $-133M in 2027, and $-93.432M in 2028.